ArriVent BioPharma, Inc. Common Stock (AVBP) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Newtown Square, 美国. 现任CEO为 Zhengbin Yao.
AVBP 拥有 IPO日期为 2024-01-26, 52 名全职员工, 在 NASDAQ Global Market, 市值为 $1.22B.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
